Evotec SE (NASDAQ:EVO - Get Free Report) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.10 and last traded at $5.18, with a volume of 512534 shares changing hands. The stock had previously closed at $7.65.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. Royal Bank of Canada raised shares of Evotec from a "sector perform" rating to an "outperform" rating in a report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "hold" rating to a "buy" rating in a research report on Friday, April 12th.
Read Our Latest Stock Report on Evotec
Evotec Price Performance
The company has a 50 day moving average of $7.38 and a 200 day moving average of $8.70.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of EVO. Quadrant Capital Group LLC bought a new position in shares of Evotec in the fourth quarter worth about $25,000. Optiver Holding B.V. lifted its holdings in Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock worth $945,000 after buying an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC acquired a new position in Evotec during the 4th quarter worth $53,931,000. Institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
